DISPATCHES FROM INTERPHEX

Kemwell Talks Expansion and Approvals in India and the US

- Last updated on GMT

Related tags: Economics, India

At this year’s Interphex, Kemwell Biopharma spoke to Outsourcing-Pharma.com about recent expansions in both India and the US.

Kemwell’s Director of Corporate Development Christian Ahlmark, spoke about the FDA approval at its manufacturing plant in Bangalore, India as well as the biologics facility - also in Bangalore – that recently opened its doors.

Kemwell recently announced 1500 sq ft of analytical lab space had been added​ in response to a contract by a major manufacturer.

However, it is not just India where Kemwell has been expanding. Ahlmark said the company was expanding its “lab footprint”​ on the East Coast in order to offer its current customers formulation development, expertise, analyticals and project management services.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more

Webinars